<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=Tizanidine</id>
	<title>Tizanidine - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=Tizanidine"/>
	<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Tizanidine&amp;action=history"/>
	<updated>2026-04-18T13:18:36Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.38.2</generator>
	<entry>
		<id>https://wikem.org/w/index.php?title=Tizanidine&amp;diff=193887&amp;oldid=prev</id>
		<title>Jonwarren: Creation of page</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Tizanidine&amp;diff=193887&amp;oldid=prev"/>
		<updated>2018-09-17T05:47:29Z</updated>

		<summary type="html">&lt;p&gt;Creation of page&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;==Administration==&lt;br /&gt;
*Type: Muscle relaxant&lt;br /&gt;
*Dosage Forms: Cap: 2mg, 4mg; Tab: 2mg, 4mg&lt;br /&gt;
*Routes of Administration: Oral&lt;br /&gt;
*Common Trade Names: Zanaflex&lt;br /&gt;
&lt;br /&gt;
==Adult Dosing==&lt;br /&gt;
===Spasticity===&lt;br /&gt;
*Individualize dose PO q6-8h prn&lt;br /&gt;
**Start 2mg PO x1&lt;br /&gt;
**Max: 3 doses/24h up to 36mg/day&lt;br /&gt;
**Taper dose 2-4 mg/day to D/C if prolonged use&lt;br /&gt;
&lt;br /&gt;
==Pediatric Dosing==&lt;br /&gt;
Safety/efficacy not established in pediatric patients&lt;br /&gt;
&lt;br /&gt;
==Special Populations==&lt;br /&gt;
===[[Drug pregnancy categories|Pregnancy Rating]]===&lt;br /&gt;
*Consider alternative during pregnancy&lt;br /&gt;
*Possible risk of fetal harm&lt;br /&gt;
&lt;br /&gt;
===Lactation risk===&lt;br /&gt;
*Consider alternative while breastfeeding&lt;br /&gt;
*Possible risk of infant sedation and hypotension&lt;br /&gt;
&lt;br /&gt;
===Renal Dosing===&lt;br /&gt;
*Adult: CrCl &amp;lt;25: Decrease dose&lt;br /&gt;
&lt;br /&gt;
===Hepatic Dosing===&lt;br /&gt;
*Adult: Not defined&lt;br /&gt;
&lt;br /&gt;
==Contraindications==&lt;br /&gt;
*Allergy to class/drug&lt;br /&gt;
*Avoid abrupt withdrawal&lt;br /&gt;
&lt;br /&gt;
==Adverse Reactions==&lt;br /&gt;
===Serious===&lt;br /&gt;
*[[Hepatotoxicity]]&lt;br /&gt;
*[[Bradycardia]], [[hypotension]]&lt;br /&gt;
*[[Syncope]]&lt;br /&gt;
*[[Hallucinations]]&lt;br /&gt;
*[[Anaphylaxis]], [[Stevens-Johnson syndrome]], exfoliative dermatitis&lt;br /&gt;
*Abrupt D/C: Rebound HTN, tachycardia, hypertonia&lt;br /&gt;
&lt;br /&gt;
===Common===&lt;br /&gt;
*[[Xerostomia]]&lt;br /&gt;
*Somnolence, [[dizziness]], nervousness&lt;br /&gt;
*[[UTI]], urinary frequency&lt;br /&gt;
*[[Constipation]], [[Vomiting]]&lt;br /&gt;
*[[Dyskinesia]]&lt;br /&gt;
&lt;br /&gt;
==Pharmacology==&lt;br /&gt;
*Half-life: 2.5 hr&lt;br /&gt;
*Metabolism: Liver; CYP450: 1A2 substrate&lt;br /&gt;
*Excretion: Urine 60%, feces 20%&lt;br /&gt;
&lt;br /&gt;
==Mechanism of Action==&lt;br /&gt;
*Binds to central alpha-2 adrenergic receptors, increasing presynaptic motor neuron inhibition and reducing spasticity&lt;br /&gt;
*Centrally acting&lt;br /&gt;
&lt;br /&gt;
==Comments==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==See Also==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category:Pharmacology]]&lt;/div&gt;</summary>
		<author><name>Jonwarren</name></author>
	</entry>
</feed>